Gradiant partnership

We’re proud to be working to tackle Huntington’s Disease, using our MISBA™ platform to upregulate FAN1 and slow down somatic expansion; the process now understood to be the driver of this devastating inherited neurodegenerative disease.

gradiant bioconvergence is a key partner in progressing our mission to develop disease-modifying therapies that halt neurodegeneration, so we are excited to see their parent (gradiant) supporting SV Health Investors’ second Dementia Discovery Fund (DDF)!

#HuntingtonsDisease #DDF #Neurodegeneration